Sign up
Pharma Capital

Inovio Pharmaceuticals reports narrower net loss in 3Q as R&D expenses decrease

The late-stage biopharma said its Phase 3 study of cancer drug VGX-3100 is set to fully enroll in 2019
Scientist sitting in a lab
Inuvio Pharmaceuticals develops DNA immunotherapies to treat cancers and infectious diseases

Inovio Pharmaceuticals Inc (NASDAQ:INO) topped earnings expectations in its third-quarter results as research and development expenses decreased.

The biotech reported a net loss of $0.27 per share on revenue of $2 million compared with a net loss of $0.39 per share on revenue of $2.65 million in the previous year’s third quarter.

The Pennsylvania-based company surpassed Wall Street estimates of a net loss of $0.30 per share but fell short of average revenue estimates of $3.34 million.

Shares were up slightly to $5.19 in Thursday after-hours trading.

READ: Inovio Pharmaceuticals’ synthetic flu vaccine could be an all-in-one solution

Operating expenses decreased to $28.6 million compared with $31.8 million in the previous third quarter.

Research and development expenses also dipped to $21.9 million compared with $25.5 million a year ago.

The company provided an update on its drug VGX-3100,a DNA-based immunotherapy designed to treat pre-cancers and cancers caused by human papillomavirus, commonly known as HPV.

“The Phase 3 REVEAL 1 study for our lead VGX-3100 program is on track to fully enroll in 2019 and our three separate immuno-oncology, checkpoint combination Phase 2 trials, being executed with top partners and collaborators, MedImmune, Genentech, and Regeneron, are also advancing well,” said CEO J. Joseph Kim in the company’s press release.

The late-stage biopharma develops DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.